DarioHealth Corp. (NASDAQ:DRIO) Short Interest Update

DarioHealth Corp. (NASDAQ:DRIO) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 80,370 shares, an increase of 32.2% from the December 15th total of 60,781 shares. Based on an average daily trading volume, of 33,153 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.2% of the shares of the company are short sold. Currently, 1.2% of the shares of the company are short sold. Based on an average daily trading volume, of 33,153 shares, the days-to-cover ratio is currently 2.4 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd boosted its stake in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 62,511 shares of the company’s stock after buying an additional 43,513 shares during the quarter. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Price Performance

DarioHealth stock opened at $12.44 on Friday. The firm has a market capitalization of $84.09 million, a PE ratio of -1.11 and a beta of 1.05. DarioHealth has a 52 week low of $5.93 and a 52 week high of $17.74. The firm’s 50-day simple moving average is $11.95 and its 200 day simple moving average is $12.07. The company has a quick ratio of 4.02, a current ratio of 4.55 and a debt-to-equity ratio of 0.41.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DRIO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Wall Street Zen raised shares of DarioHealth from a “sell” rating to a “hold” rating in a research note on Saturday. Stifel Nicolaus set a $16.00 price objective on shares of DarioHealth in a research report on Friday, November 14th. Finally, Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $32.00.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.